查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046917

強迫症藥物市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、地區和競爭格局分類，2021-2031年

Obsessive-Compulsive Disorder Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (SSRI, TCA ), By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球強迫症 (OCD) 藥物市場預計將從 2025 年的 8.9314 億美元成長到 2031 年的 13.9074 億美元，複合年成長率為 7.66%。

強迫症 (OCD) 的藥物主要包括選擇性血清素再回收抑制劑(SSRI) 和三環抗憂鬱藥物，這些藥物用於調節神經傳導物質活性，緩解強迫性思維和強迫行為等症狀。市場促進因素包括人們對精神疾病的認知不斷提高，從而提高了診斷率，以及新興經濟體對醫療基礎設施投資的增加。這些潛在因素正在積極擴大可診斷的患者群體，並支持對長期藥物治療策略的持續需求。市場擴張的主要障礙是誤診率高以及症狀出現到開始治療之間存在顯著延遲，這減緩了藥物研發公司的產生收入。儘管強迫症在全球範圍內廣泛流行，但這種診斷差距極大地限制了可利用的市場規模。根據國際強迫症基金會估計，到 2025 年，全球將有約 2.4 億人患有強迫症。這凸顯了一個尚未滿足的巨大需求：改善診斷系統對於確保這些治療方案能夠惠及目標族群至關重要。

市場概覽
預測期 2027-2031
市場規模：2025年 8.9314億美元
市場規模：2031年 1,390,740,000 美元
複合年成長率：2026-2031年 7.66%
成長最快的細分市場 選擇性血清素再回收抑制劑
最大的市場 北美洲

市場促進因素

強迫症（OCD）在全球的盛行率不斷上升，是推動市場擴張的主要動力，需要藥物治療的患者群體持續顯著成長。隨著我們對該疾病流行病學的理解不斷加深，已確定的目標市場規模遠超先前的估計值。貝勒醫學院2024年7月發表的一項關於深部腦部刺激的研究表明，強迫症影響著全球約2-3%的人口。此疾病的普遍性凸顯了開發可擴充性治療方案的迫切需求，以滿足全球數百萬患者的需求，尤其需要提高標準療法的處方量，並促進價格合理的藥物療法商業化，從而有效控制慢性症狀。新型治療機制和在研藥物的研發正在重塑競爭格局，將研究重點從傳統的基於血清素的療法轉向麩胺酸調節等創新標靶。製藥開發商正積極投資後期臨床試驗，以期推出能夠快速治療難治性病例的藥物。例如，Biohaven Ltd.預計在2025年上半年公佈其首個強迫症3期臨床試驗的主要數據，該試驗利用了其麩胺酸調節平台。隨著市場努力彌合治療延誤造成的缺口，這些臨床里程碑至關重要。根據NOCD於2024年4月發布的報告，成年人平均需要14至17年才能獲得準確診斷並開始有效治療。這些基於機制的治療方法的進展旨在縮短漫長的治療過程，並解決現有藥物療法的局限性，從而獲得顯著的市場佔有率。

市場挑戰

高誤診率和症狀出現到開始治療之間的漫長等待時間嚴重阻礙了全球強迫症（OCD）藥物市場的成長。這種診斷差距如同一個瓶頸，人為地限制了目標市場規模，使製藥公司無法觸及大多數潛在患者群。由於社會歧視，患者往往隱藏症狀，並且經常被全科醫生誤診為整體焦慮症或憂鬱症，導致錯失早期藥物干預的機會。因此，製藥公司面臨理論盛行率與實際處方量之間的差異，直接影響藥物研發公司的收入預測和投資報酬率。這種患者識別效率低下意味著，絕大多數受影響人群多年來都無法獲得藥物。根據國際強迫症基金會的數據，2025年的一項臨床數據分析將顯示，在醫療機構中，超過80%表現出強迫症（OCD）症狀的個體仍未被確診。這項統計數據表明，市場停滯並非由於需求不足，而是由於當前的醫療基礎設施無法準確識別和獲取維持製藥公司商業性成長所需的患者群體。

市場趨勢

藥物基因體學學在個人化醫療中的應用正在改變市場格局，將臨床治療模式從「試驗錯式藥物管理」轉變為「基於基因洞察的精準醫療」。這一趨勢的驅動力源於近期在疾病遺傳結構理解方面的突破，這些突破使得標靶治療性介入能夠識別特定的生物標記。發表於2025年6月《自然遺傳學》雜誌的一篇題為「全基因組分析鑑定出30個與強迫症相關的基因位點」的綜合性薈萃分析，成功鑑定了30個獨立的全基因組顯著性基因位點，為加速開發針對標準血清素能療法無效患者的新型、基於見解的候選藥物提供了重要藥物。同時，數位治療方法作為輔助性治療的普及，透過整合實證行為介入和藥物治療，正在改變患者管理模式，進而提升治療效果。這些數位平台因其能夠提供擴充性且高保真度的暴露和反應預防而日益受到認可，從而解決了普遍缺乏專業護理的難題。根據NOCD於2025年2月發布的題為「NOCD療法在一項針對強迫症（OCD）兒童和青少年的新研究中取得突破性成果」的公告，大規模臨床評估顯示，使用這種虛擬療法模式的患者症狀嚴重程度降低了近40%，證明了數字療法作為傳統藥物療法的有力輔助性治療的有效性。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：強迫症藥物的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（SSRI（選擇性血清素再回收抑制劑）、TCA（三環抗憂鬱藥物））
    • 透過申請（研究機構、醫院/診所等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美強迫症藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲強迫症藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區強迫症藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲強迫症藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲強迫症藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球強迫症藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott SA
  • Eli Lilly, and Company
  • Viatria Inc.
  • H. LUNDBECK A/S,
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Zydus Pharmaceuticals, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Amneal Pharmaceuticals LLC
  • Teva Pharmaceutical industries Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17503

The Global Obsessive-Compulsive Disorder Drugs Market is projected to grow from USD 893.14 Million in 2025 to USD 1390.74 Million by 2031, at a 7.66% CAGR. Obsessive-Compulsive Disorder drugs represent a class of pharmaceutical agents, primarily Selective Serotonin Reuptake Inhibitors and tricyclic antidepressants, formulated to regulate neurotransmitter activity and alleviate symptoms of intrusive thoughts and compulsive behaviors. Primary market drivers include the escalating recognition of mental health conditions, leading to higher diagnosis rates, and increasing investment in psychiatric healthcare infrastructure across emerging economies. These fundamental forces actively expand the diagnosable patient base and support the sustained demand for long-term pharmacological management strategies. A significant impediment to market scalability is the high rate of misdiagnosis and the considerable latency between symptom onset and treatment initiation, which delays revenue generation for therapeutic developers. This diagnostic gap significantly restricts the accessible market size despite the widespread prevalence of the condition globally. The International OCD Foundation estimated that nearly 240 million individuals worldwide would be living with Obsessive-Compulsive Disorder in 2025, highlighting an immense unmet need that necessitates improved diagnostic frameworks to ensure these therapeutic solutions reach the affected population.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 893.14 Million
Market Size 2031USD 1390.74 Million
CAGR 2026-20317.66%
Fastest Growing SegmentSelective Serotonin Reuptake Inhibitors
Largest MarketNorth America

Market Driver

The rising global prevalence of Obsessive-Compulsive Disorder acts as a primary catalyst for market expansion, creating a substantial and growing patient pool necessitating pharmacological intervention. As the understanding of the disorder's epidemiology improves, the identified addressable market widens significantly beyond historical estimates. According to Baylor College of Medicine in July 2024, a study on deep brain stimulation highlighted that Obsessive-Compulsive Disorder affects approximately 2-3% of the worldwide population. This ubiquitous nature of the condition underscores the urgent demand for scalable therapeutic solutions that can address the needs of millions of sufferers globally, specifically driving the volume of prescriptions for standard-of-care treatments and incentivizing the commercialization of accessible drug therapies for effective chronic symptom management. Advancements in novel therapeutic mechanisms and drug pipelines are reshaping the competitive landscape by shifting focus from traditional serotonergic treatments to innovative targets such as glutamate modulation. Pharmaceutical developers are actively investing in late-stage clinical trials to introduce agents that offer rapid efficacy for treatment-resistant cases. For instance, Biohaven Ltd. anticipated reporting topline data from its first Phase 3 trial in Obsessive-Compulsive Disorder in the first half of 2025, leveraging its glutamate modulating platform. Such clinical milestones are critical as the market seeks to bridge the gap caused by delayed treatment; according to NOCD in April 2024, receiving an accurate diagnosis and effective treatment can take 14 to 17 years on average for adults. These advancements in mechanism-based therapies aim to shorten this therapeutic odyssey and capture significant market share by addressing the limitations of current pharmacotherapy.

Market Challenge

The high rate of misdiagnosis and the extended latency between symptom onset and treatment initiation severely hamper the growth of the Global Obsessive-Compulsive Disorder Drugs Market. This diagnostic gap acts as a bottleneck, artificially restricting the addressable market size and preventing pharmaceutical companies from reaching a large portion of the potential patient population. Symptoms are frequently concealed by patients due to stigma or misinterpreted by general practitioners as generalized anxiety or depression, often causing the window for early pharmacological intervention to be missed. Consequently, manufacturers face a discrepancy between the theoretical prevalence of the condition and the actual volume of prescriptions generated, which directly impacts revenue projections and return on investment for therapeutic developers. This inefficiency in patient identification ensures that a vast majority of the affected population remains outside the pharmaceutical consumer base for years. According to the International OCD Foundation, an analysis of clinical data in 2025 revealed that over 80% of individuals exhibiting symptoms consistent with Obsessive-Compulsive Disorder in healthcare settings were not formally diagnosed. This statistical evidence underscores that the market's stagnation is not due to a lack of demand, but rather the inability of the current healthcare infrastructure to accurately identify and capture the patient pool required to sustain commercial growth for drug manufacturers.

Market Trends

The adoption of pharmacogenomics for personalized treatment is transforming the market by shifting clinical approaches from trial-and-error medication management to genetically informed precision care. This trend is driven by recent breakthroughs in understanding the genetic architecture of the condition, which enables the identification of specific biological markers for targeted therapeutic intervention. According to Nature Genetics in June 2025, a comprehensive meta-analysis titled 'Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder' successfully identified 30 independent genome-wide significant loci, providing critical insights that facilitate the development of novel, mechanism-based drug candidates for patients who do not respond to standard serotonergic treatments. The proliferation of digital therapeutics as adjunct care is simultaneously reshaping patient management by integrating evidence-based behavioral interventions with pharmacological regimens to enhance treatment outcomes. These digital platforms are increasingly recognized for their ability to deliver scalable, high-fidelity exposure and response prevention therapy, thereby addressing the widespread lack of accessible specialized care. According to NOCD in February 2025, an extensive clinical evaluation of 2,173 participants in 'NOCD Therapy Shows Groundbreaking Results in a New Study of Children and Teens with OCD' demonstrated that patients utilizing this virtual therapeutic model achieved a nearly 40% reduction in symptom severity, validating digital modalities as potent adjuncts to traditional pharmacotherapy.

Key Market Players

  • Abbott SA
  • Eli Lilly, and Company
  • Viatria Inc.
  • H. LUNDBECK A/S,
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Zydus Pharmaceuticals, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Amneal Pharmaceuticals LLC
  • Teva Pharmaceutical industries Ltd.

Report Scope

In this report, the Global Obsessive-Compulsive Disorder Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Obsessive-Compulsive Disorder Drugs Market, By Type

  • SSRI (Selective Serotonin Reuptake Inhibitors)
  • TCA (Tricyclic Antidepressant)

Obsessive-Compulsive Disorder Drugs Market, By Application

  • Research Institute
  • Hospitals & Clinics
  • Others

Obsessive-Compulsive Disorder Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Obsessive-Compulsive Disorder Drugs Market.

Available Customizations:

Global Obsessive-Compulsive Disorder Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Obsessive-Compulsive Disorder Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (SSRI (Selective Serotonin Reuptake Inhibitors), TCA (Tricyclic Antidepressant))
    • 5.2.2. By Application (Research Institute, Hospitals & Clinics, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Obsessive-Compulsive Disorder Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Obsessive-Compulsive Disorder Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Obsessive-Compulsive Disorder Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Obsessive-Compulsive Disorder Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application

7. Europe Obsessive-Compulsive Disorder Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Obsessive-Compulsive Disorder Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. France Obsessive-Compulsive Disorder Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Obsessive-Compulsive Disorder Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Obsessive-Compulsive Disorder Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Obsessive-Compulsive Disorder Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Asia Pacific Obsessive-Compulsive Disorder Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Obsessive-Compulsive Disorder Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. India Obsessive-Compulsive Disorder Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Obsessive-Compulsive Disorder Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Obsessive-Compulsive Disorder Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Obsessive-Compulsive Disorder Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. Middle East & Africa Obsessive-Compulsive Disorder Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Obsessive-Compulsive Disorder Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Obsessive-Compulsive Disorder Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Obsessive-Compulsive Disorder Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. South America Obsessive-Compulsive Disorder Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Obsessive-Compulsive Disorder Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Obsessive-Compulsive Disorder Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Obsessive-Compulsive Disorder Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Obsessive-Compulsive Disorder Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott SA
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Eli Lilly, and Company
  • 15.3. Viatria Inc.
  • 15.4. H. LUNDBECK A/S,
  • 15.5. GlaxoSmithKline plc
  • 15.6. Pfizer Inc.
  • 15.7. Zydus Pharmaceuticals, Inc.
  • 15.8. Lupin Pharmaceuticals, Inc.
  • 15.9. Amneal Pharmaceuticals LLC
  • 15.10. Teva Pharmaceutical industries Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer